Fidelity Investments’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-2,867,572
| Closed | -$8.52M | – | 2773 |
|
|
2016
Q3 | $8.52M | Buy |
2,867,572
+8,000
| +0.3% | +$13.9K | ﹤0.01% | 2043 |
|
|
2016
Q2 | $4.26M | Sell |
2,859,572
-234,904
| -8% | -$537K | ﹤0.01% | 2220 |
|
|
2016
Q1 | $11.4M | Sell |
3,094,476
-1,186,788
| -28% | -$7.35M | ﹤0.01% | 1903 |
|
|
2015
Q4 | $43.2M | Hold |
4,281,264
| – | – | 0.01% | 1311 |
|
|
2015
Q3 | $58.2M | Buy |
4,281,264
+357
| +0% | +$6.36K | 0.01% | 1180 |
|
|
2015
Q2 | $81.2M | Hold |
4,280,907
| – | – | 0.01% | 1130 |
|
|
2015
Q1 | $112M | Buy |
4,280,907
+851,379
| +25% | +$21.7M | 0.01% | 976 |
|
|
2014
Q4 | $71.8M | Sell |
3,429,528
-847,710
| -20% | -$21.4M | 0.01% | 1168 |
|
|
2014
Q3 | $143M | Buy |
4,277,238
+501,926
| +13% | +$15.6M | 0.02% | 808 |
|
|
2014
Q2 | $121M | Sell |
3,775,312
-636,349
| -14% | -$23.7M | 0.02% | 898 |
|
|
2014
Q1 | $203M | Buy |
4,411,661
+128,265
| +3% | +$7.52M | 0.03% | 643 |
|
|
2013
Q4 | $304M | Buy |
4,283,396
+1,522,267
| +55% | +$116M | 0.04% | 450 |
|
|
2013
Q3 | $237M | Sell |
2,761,129
-825,647
| -23% | -$70M | 0.04% | 539 |
|
|
2013
Q2 | $227M | Buy |
+3,586,776
| New | +$190M | 0.04% | 531 |
|
Fidelity Investments's AEGR Position: Q4 2016 in Review
Fidelity Investments sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 2,867,572 shares — an estimated $8.52M sold.
Fidelity Investments first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $304M in Q4 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Fidelity Investments reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Fidelity Investments sold 2,867,572 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $8.52M.
- Fidelity Investments first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Fidelity Investments's Aegerion Pharmaceuticals position peaked at $304M in Q4 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Fidelity Investments's 13F filing for Q4 2016, filed 10 Feb 2017.